Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab

Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.
Latest website image capture
Clouds background image

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now shows an updated revision label: v3.3.2, replacing the previous v3.2.0.
    Difference
    0.0%
    Check dated 2025-11-25T14:43:06.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The funding-status notice that previously appeared on the ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T07:28:28.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Entries for postcodes 70403 and 71004 were updated from Tainan City, Taiwan to Tainan, Taiwan, and the new locations were added.
    Difference
    0.1%
    Check dated 2025-11-11T03:15:04.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Minor administrative update to the study record, such as a new last update timestamp, with no changes to core study design, eligibility criteria, interventions, or primary outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-10-27T20:56:09.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.
    Difference
    4%
    Check dated 2025-10-06T07:55:59.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Overall, the page has been updated to a new version (v3.1.0) with the removal of a prior disease reference (Head and neck squamous cell carcinoma).
    Difference
    0.4%
    Check dated 2025-09-29T04:15:44.000Z thumbnail image

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab

Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.